- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia
- Interventions
- Enlicitide Decanoate, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 45 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Interventions
- Enlicitide Decanoate, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 7
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more
- Conditions
- Hypercholesterolemia
- Interventions
- Enlicitide, Ezetimibe, Bempedoic Acid, Placebo for Enlicitide, Placebo for Ezetimibe, Placebo for Bempedoic Acid
- Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Lincoln, California • Flossmoor, Illinois • Louisville, Kentucky + 4 more
- Conditions
- Hyperlipidemia
- Interventions
- Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia
- Interventions
- Enlicitide Decanoate, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Daphne, Alabama • Boca Raton, Florida • Cutler Bay, Florida + 10 more
- Conditions
- Lipoprotein(a)
- Interventions
- MK-7262, Enlicitide, Placebo for MK-7262, Placebo for enlicitide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 24
- States / cities
- Alexander City, Alabama • Mobile, Alabama • Beverly Hills, California + 21 more
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia
- Interventions
- Enclitide Chloride, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Sacramento, California • Santa Ana, California + 17 more
- Conditions
- Healthy, Hypercholesterolemia
- Interventions
- Enlicitide Chloride, Placebo
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas